Aktis Oncology Director Ken Herrmann Exercises Options, Sells Shares

What Happened

• Ken Herrmann, a director of Aktis Oncology (AKTS), exercised vested options and immediately sold the resulting shares on July 20, 2026. He exercised 3,506 options at $0.08 (cost $280) and 1,350 options at $1.91 (cost $2,579). He then sold those 3,506 and 1,350 shares in the open market at a weighted average price of $24.56, generating total gross proceeds of about $119,274.
• The Form 4 also records the derivative interests as disposed at $0.00, which reflects the conversion/cancellation of the options upon exercise. Footnote F2 confirms the options were fully vested.

Key Details

• Transaction date: July 20, 2026.
• Exercise details: 3,506 shares @ $0.08 ($280); 1,350 shares @ $1.91 ($2,579).
• Sale details: 4,856 shares sold at weighted average $24.56; total proceeds ≈ $119,274. Footnote F1: sale prices ranged $24.50–$24.66.
• Shares owned after transaction: Not specified in the filed Form 4 provided.
• Filing timeliness: Report filed July 21, 2026 — within the SEC’s reporting window (timely).
• Transaction codes: M = option exercise; S = open market sale.

Context

• This was an exercise-and-sell (cashless) transaction: Herrmann exercised vested options and sold the shares the same day. Net proceeds are roughly the sale proceeds minus the exercise costs (≈ $119.3K − $2.9K ≈ $116.4K), before taxes and fees.
• Such same-day exercises and sales are common for option-holders looking to realize value from vested awards and do not, by themselves, indicate the insider’s future view of the company.